Literature DB >> 18544205

Tuberculosis culture testing at a tertiary care hospital: options for improved management and use for treatment decisions.

M E Edginton1, L Rakgokong, S Verver, S A Madhi, H J Koornhof, M L Wong, H J Hodkinson.   

Abstract

SETTING: Chris Hani Baragwanath Hospital, a tertiary care hospital in Johannesburg, South Africa.
OBJECTIVES: To determine the proportion of patients with positive Mycobacterium tuberculosis cultures and whether those who were positive were on treatment.
DESIGN: Tuberculosis (TB) culture results were obtained from the laboratory for a 3-month period. Positive results were checked against registrations at the hospital TB Care Centre (TBCC). The treatment status of non-registered patients was obtained from various records at the hospital, district clinics and from home visits.
RESULTS: Overall, 3909 patients had 5404 samples sent for culture. Of these, 708 patients (18%) had at least one positive culture. The positive yield from 2749 adult sputum samples was 33% and ranged from 6% to 40% for different extra-pulmonary specimens. Among 1160 children, the yield varied from 0% to 12%, with 12% in sputum and gastric washing specimens. Of the 708 culture-positive patients, 429 (61%) patients were registered at the TBCC and were known to have started TB treatment. Of the 279 subjects not registered (39% overall), 100 (36%) died. Only 67 of the 179 survivors were confirmed on treatment, 40 were not on treatment and 72 could not be traced.
CONCLUSIONS: Large numbers of TB culture tests were performed, some inappropriately. Study findings highlight inadequacies in the management of culture-confirmed TB at this hospital.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544205

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  1 in total

1.  Urban movement and alcohol intake strongly predict defaulting from tuberculosis treatment: an operational study.

Authors:  Ibrahim Sendagire; Maarten Schim Van der Loeff; Andrew Kambugu; Joseph Konde-Lule; Frank Cobelens
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.